IL209967A - Peptides capable of inducing cytotoxic lymphocyte (ctl), medicinal preparations containing them and their use and in vitro methods of inducing ctl - Google Patents

Peptides capable of inducing cytotoxic lymphocyte (ctl), medicinal preparations containing them and their use and in vitro methods of inducing ctl

Info

Publication number
IL209967A
IL209967A IL209967A IL20996710A IL209967A IL 209967 A IL209967 A IL 209967A IL 209967 A IL209967 A IL 209967A IL 20996710 A IL20996710 A IL 20996710A IL 209967 A IL209967 A IL 209967A
Authority
IL
Israel
Prior art keywords
ctl
lymphocyte
cytotoxic
peptides
induce
Prior art date
Application number
IL209967A
Other languages
English (en)
Hebrew (he)
Other versions
IL209967A0 (en
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of IL209967A0 publication Critical patent/IL209967A0/en
Publication of IL209967A publication Critical patent/IL209967A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL209967A 2008-06-19 2010-12-13 Peptides capable of inducing cytotoxic lymphocyte (ctl), medicinal preparations containing them and their use and in vitro methods of inducing ctl IL209967A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7406208P 2008-06-19 2008-06-19
US19759908P 2008-10-28 2008-10-28
PCT/JP2009/002771 WO2009153992A1 (en) 2008-06-19 2009-06-18 Cdca1 epitope peptides and vaccines containing the same

Publications (2)

Publication Number Publication Date
IL209967A0 IL209967A0 (en) 2011-02-28
IL209967A true IL209967A (en) 2015-09-24

Family

ID=41433910

Family Applications (1)

Application Number Title Priority Date Filing Date
IL209967A IL209967A (en) 2008-06-19 2010-12-13 Peptides capable of inducing cytotoxic lymphocyte (ctl), medicinal preparations containing them and their use and in vitro methods of inducing ctl

Country Status (16)

Country Link
US (2) US9387238B2 (enExample)
EP (1) EP2303912B1 (enExample)
JP (1) JP5640262B2 (enExample)
KR (2) KR20160119264A (enExample)
CN (1) CN102119171B (enExample)
AU (1) AU2009261382B2 (enExample)
BR (1) BRPI0914782B1 (enExample)
CA (1) CA2728268C (enExample)
DK (1) DK2303912T3 (enExample)
ES (1) ES2658842T3 (enExample)
IL (1) IL209967A (enExample)
MX (1) MX2010014044A (enExample)
RU (1) RU2502740C2 (enExample)
SG (1) SG191680A1 (enExample)
TW (1) TWI526219B (enExample)
WO (1) WO2009153992A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1907582B1 (en) 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
ES2537323T3 (es) 2007-08-20 2015-06-05 Oncotherapy Science, Inc. Péptido CDCA1 y agente farmacéutico que lo comprende
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2013071154A1 (en) * 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
EP2872532A4 (en) * 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
ES2900004T3 (es) 2013-08-05 2022-03-15 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (NSCLC)
JP6700512B2 (ja) * 2014-08-04 2020-05-27 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
TW202023581A (zh) * 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
EP0983357A1 (en) 1997-05-23 2000-03-08 Biogen, Inc. Modulators of tissue regeneration
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
AU749544B2 (en) 1998-06-25 2002-06-27 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen peptides originating in cyclophilin B
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US20030170255A1 (en) 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020172952A1 (en) 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1196565A2 (en) 1999-06-30 2002-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2384713A1 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
AR031250A1 (es) 2000-07-11 2003-09-17 Corixa Corp Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
WO2003025010A2 (en) 2001-09-17 2003-03-27 Eirx Therapeutics Limited Human delta-n p73 molecules and uses thereof
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
EP1519736A2 (en) 2002-06-12 2005-04-06 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
EP2267023B1 (en) 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CN1703522A (zh) 2002-09-30 2005-11-30 肿瘤疗法科学股份有限公司 诊断睾丸精原细胞瘤的方法
CA2500521A1 (en) * 2002-10-02 2004-09-23 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20040224408A1 (en) 2002-12-10 2004-11-11 Jean-Philippe Girard THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
CN1898563B (zh) 2003-09-24 2011-11-23 肿瘤疗法科学股份有限公司 诊断乳腺癌的方法
TW200533376A (en) 2004-03-24 2005-10-16 Oncotherapy Science Inc Compositions and methods for treating lung cancer
US7998695B2 (en) 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
EP2305811A1 (en) 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
EP1907582B1 (en) 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
WO2007013480A2 (en) 2005-07-29 2007-02-01 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
US7776341B2 (en) 2006-08-10 2010-08-17 Colorado State University Research Foundation Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens
UA100127C2 (ru) 2007-08-20 2012-11-26 Онкотерапи Саенс, Инк. Пептид cdh3 и лекарственное средство, содержащее его
ES2537323T3 (es) * 2007-08-20 2015-06-05 Oncotherapy Science, Inc. Péptido CDCA1 y agente farmacéutico que lo comprende
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
WO2011030329A1 (en) 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
EP2872532A4 (en) * 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH

Also Published As

Publication number Publication date
JP2011524737A (ja) 2011-09-08
MX2010014044A (es) 2011-03-03
US10711047B2 (en) 2020-07-14
WO2009153992A1 (en) 2009-12-23
RU2011101709A (ru) 2012-07-27
RU2502740C2 (ru) 2013-12-27
SG191680A1 (en) 2013-07-31
EP2303912B1 (en) 2018-01-03
JP5640262B2 (ja) 2014-12-17
US9387238B2 (en) 2016-07-12
BRPI0914782A2 (pt) 2016-07-26
CA2728268A1 (en) 2009-12-23
KR20160119264A (ko) 2016-10-12
KR101705011B1 (ko) 2017-02-23
US20110189214A1 (en) 2011-08-04
BRPI0914782B1 (pt) 2021-08-31
KR20110031314A (ko) 2011-03-25
DK2303912T3 (en) 2018-03-12
TWI526219B (zh) 2016-03-21
TW201000120A (en) 2010-01-01
ES2658842T3 (es) 2018-03-12
AU2009261382B2 (en) 2013-08-15
EP2303912A4 (en) 2012-08-29
CA2728268C (en) 2017-11-07
US20160272692A1 (en) 2016-09-22
EP2303912A1 (en) 2011-04-06
AU2009261382A1 (en) 2009-12-23
IL209967A0 (en) 2011-02-28
CN102119171B (zh) 2014-08-06
CN102119171A (zh) 2011-07-06

Similar Documents

Publication Publication Date Title
IL275854A (en) Pharmaceutical composition and its administration
ZA201102645B (en) Method for delivering a pharmaceutical composition to patient in need thereof
ZA201304728B (en) Boronate ester conpoundds and pharmaceutical compositions thereof
IL221542A (en) Formulations for oral administration of intestinal adsorbents
IL203292A (en) History of n-indazolil affluent, process for preparation, intermediates obtained in this process and pharmacological preparations containing the history
IL215773A (en) Acetidinyl Diamides, Pharmaceuticals containing them and their uses
EP2143424A4 (en) ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
IL199554B (en) Cyclopamine-like compounds and their use for the preparation of anti-proliferative drugs
IL217912A (en) History of 5-Amino-1-Benzimidazole-Pyrazole and Pharmaceutical Preparations Containing It
IL207512A0 (en) Pharmaceutical composition for poorly soluble drugs
EP2615913A4 (en) EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN
PT2152195E (pt) Produto farmacêutico peptídico para distribuição oral
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
IL214175A (en) Derivatives of aminotetralin, their pharmaceutical compositions and their use
IL219947A (en) Cyclic peptides and pharmaceutical preparations containing them
IL204521A0 (en) Oxadiazole derivatives, their preparation and pharmaceutical compositions containing them
IL216171A (en) Lipidic Compound, Method for Preparing the Compound, Pharmaceutical and Lipid Preparations Containing Their Composition and Uses
IL211683A0 (en) 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
ZA201100615B (en) Appetising medicament for oral administration in solid form
IL220097A (en) Pharmaceutical preparation containing oligopeptides
IL215498A0 (en) Oxadiazole derivatives and pharmaceutical compositions containing them
IL217500A0 (en) Tetrazole derivatives, their preparartion and pharmaceutical compositions containing them
PL2154966T3 (pl) Benzoimidazole i ich kompozycje farmaceutyczne
PL399450A1 (pl) Utrzymujace sie w zoladku kompozycje farmaceutyczne do natychmiastowego i przedluzonego uwalniania acetaminofenu
PL2391351T3 (pl) Kompozycje farmaceutyczne zawierające pochodne 2-okso-1-pirolidyny

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed